Astrazeneca PLC (NYSE:AZN) was downgraded by equities researchers at TheStreet to a “hold” rating in a research report issued on Friday.
Other equities analysts also recently issued research reports about the stock. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Monday, August 8th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Monday, June 27th. Citigroup Inc. reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Saturday, June 25th. Bank of America Corp. reissued a “buy” rating and issued a $36.65 target price on shares of Astrazeneca PLC in a research note on Monday, July 18th. Finally, Argus raised shares of Astrazeneca PLC from a “hold” rating to a “buy” rating and set a $38.00 target price on the stock in a research note on Monday, August 29th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. Astrazeneca PLC currently has an average rating of “Hold” and an average target price of $37.56.
Astrazeneca PLC (NYSE:AZN) traded down 0.6813% during mid-day trading on Friday, hitting $30.6299. 646,525 shares of the stock traded hands. The company has a market cap of $77.49 billion, a price-to-earnings ratio of 35.0056 and a beta of 0.75. Astrazeneca PLC has a 12 month low of $26.97 and a 12 month high of $35.04. The stock’s 50 day moving average is $32.95 and its 200-day moving average is $30.86.
Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings results on Thursday, July 28th. The company reported $0.83 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.76 by $0.07. The company had revenue of $5.60 billion for the quarter, compared to the consensus estimate of $5.56 billion. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. Astrazeneca PLC’s revenue was down 4.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.21 earnings per share. On average, equities research analysts anticipate that Astrazeneca PLC will post $2.97 EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Premier Asset Managment LLC raised its position in Astrazeneca PLC by 83.9% in the third quarter. Premier Asset Managment LLC now owns 45,760 shares of the company’s stock valued at $1,503,000 after buying an additional 20,875 shares during the period. Fox Run Management L.L.C. acquired a new position in Astrazeneca PLC during the third quarter valued at approximately $417,000. Atria Investments LLC purchased a new stake in shares of Astrazeneca PLC during the third quarter valued at $349,000. Creative Planning increased its stake in shares of Astrazeneca PLC by 29.6% in the third quarter. Creative Planning now owns 36,581 shares of the company’s stock valued at $1,202,000 after buying an additional 8,353 shares in the last quarter. Finally, Raymond James Trust N.A. increased its stake in shares of Astrazeneca PLC by 80.9% in the third quarter. Raymond James Trust N.A. now owns 42,952 shares of the company’s stock valued at $1,410,000 after buying an additional 19,209 shares in the last quarter. 11.39% of the stock is owned by institutional investors and hedge funds.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.